Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Leukemia and Lymphoma is Scopus-indexed (Q2, CiteScore 3.9), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 1029-2403Verify ISSN ↗1042-8194Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Hematology | 63 / 151 | 58th | Q2 |
| Oncology | 224 / 428 | 47th | Q3 |
| Cancer Research | 162 / 233 | 30th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1989–present, best quartile Q2, CiteScore 3.9.
Leukemia and Lymphoma is Q2 in Hematology (rank 63 of 151), Q3 in Oncology (rank 224 of 428) and Q3 in Cancer Research (rank 162 of 233), by CiteScore 2025.
Leukemia and Lymphoma is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.9, which places it in quartile Q2 at the 58th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.861, quartile Q2, with an H-index of 109.
Leukemia and Lymphoma is published by Taylor and Francis Ltd. Its print ISSN is 1029-2403 and its online ISSN is 1042-8194.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Leukemia and Lymphoma has an h-index of 118 and a 2-year mean of 1.69 citations per paper (OpenAlex). Its Scopus CiteScore is 3.9, quartile Q2. On 2-year citations it ranks #63 of 148 Scopus journals in Hematology.
Leukemia and Lymphoma published 349 papers in 2025; its busiest recent year was 2020 with 542. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from United States (37.9%), Japan (10.5%) and China (9.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 25 retracted papers are recorded (1.7 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.